Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-13, Stock:LLY, The news for the past five days is as follows:
2018-04-06: NEWS1: Noteworthy ETF Inflows: VTV, USB, LLY, MS.NEWS2: Noteworthy ETF Inflows: VTV, USB, LLY, MS.NEWS3: Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus.NEWS4: Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus.NEWS5: Pharma Stock Roundup: LLY&apos;s Cyramza Shines in Cancer Study, PFE & AZN in Focus.NEWS6: Wired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival.
2018-04-09: NEWS1: We Did The Math USMV Can Go To $58.NEWS2: We Did The Math USMV Can Go To $58.
2018-04-10: NEWS1: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS2: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS3: AbbVie&apos;s RA Candidate Meets Primary Endpoints in Phase III.NEWS4: vTv Therapeutics Crashes on Alzheimer's Drug Study Failure.NEWS5: vTv Therapeutics Crashes on Alzheimer's Drug Study Failure.NEWS6: Merck's Keytruda Offers Survival Benefit in Lung Cancer Study.NEWS7: Merck's Keytruda Offers Survival Benefit in Lung Cancer Study.NEWS8: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS9: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS10: Top Ranked Growth Stocks to Buy for April 10th.NEWS11: How Bristol-Myers Squibb Stock Performed in 1Q18.
2018-04-11: NEWS1: Novartis’s Valuation and Analysts’ Recommendations on April 11.NEWS2: Incyte Expected to Report Robust Revenue Growth in Fiscal 2018.NEWS3: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS4: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS5: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS6: A Look at Eli Lilly’s 1Q18 Stock Performance.
2018-04-12: NEWS1: Pfizer's Deal Potential Doesn't Stop at Bristol-Myers.NEWS2: Olumiant Could Boost Incyte’s Revenues.NEWS3: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS4: Incyte Has Diversified Its Revenues across Multiple Product Lines.

Answer: Rise